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ABSTRACT Objective: Recently emerged beta-coronavirus SARS-CoV-2, has resulted in the current pandemic designated COVID-19. COVID-19 manifests as severe illness exhibiting systemic inflammatory
response syndrome, acute respiratory distress syndrome (ARDS), thrombotic events, and shock, exacerbated
further by co-morbidities and age. Recent clinical evidence suggests that the development of ARDS and
subsequent pulmonary failure result from a complex interplay between cell types (endothelial, epithelial
and immune) within the lung promoting inflammatory infiltration and a pro-coagulative state. How the
complex molecular events mediated by SARS-CoV-2 in infected lung epithelial cells lead to thrombosis
and pulmonary failure, is yet to be fully understood. Methods: We address these questions here, using
publicly available transcriptomic data in the context of lung epithelia affected by SARS-CoV-2 and other
respiratory infections, in vitro. We then extend our results to the understanding of in vivo lung, using a
publicly available COVID-19 lung transcriptomic study. Results and Conclusions: Our analysis indicates that
there exists a complex interplay between the fibrinolytic system particularly plasmin, and the complement
and platelet-activating systems upon SARS-CoV-2 infection, with a potential for therapeutic intervention.
INDEX TERMS COVID-19, plasminogen activators, thrombosis, complement system, neutrophil extracel-

lular traps (NETs).
IMPACT STATEMENT

Why does COVID-19 lead to thrombotic complications in critically ill patients? We
address this question by reconstructing mechanisms unique to COVID-19, from lung-epithelial transcriptional data, leading to potential therapeutic interventions.

I. INTRODUCTION

Recent studies [1], [2] have rapidly provided molecular insights into the pathogenicity of the SARS-CoV-2, mainly at
the level of genomic, structural, and functional aspects of
viral-host interactions. Further, studies have identified key
pathophysiological and molecular events associated with infection pathogenesis and progression of COVID-19 including
thrombocytopenia, lymphopenia, eosinophilia, and elevated
lactate dehydrogenase and fibrinogen [3], [4]. The molecular

findings have included a delayed interferon (IFN) response
type I and III [5], [6] with a concomitant increase of proinflammatory cytokines (namely IL-17, IL-6 and/or IL-1B) [7]
leading to a “cytokine” storm coupled with the depletion of
markers for platelets, natural killer cells, and dysregulation of
CD4+ and B-cell lymphocyte populations [8]. In contrast to
other respiratory viral infections (e.g., refs [9]–[12]), SARSCoV-2 can efficiently replicate in cells of various tissues that
express angiotensin-converting enzyme 2 (ACE2) and host
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serine protease (TMPRSS2) [13], [14], thus contributing to
the increased transmissibility and lower-lung pathogenicity in
humans [15]. This observation led us to explore mechanisms
unique to SARS-CoV-2 infection of lung epithelial cells and
cause thrombotic events.
II. RESULTS
A. COMPARING THE SARS-COV-2 TRANSCRIPTOMIC
PROFILE WITH OTHER UPPER-RESPIRATORY TRACT
INFECTIONS

In this study, we utilized publicly available RNA-sequencing
data [5] (GSE100457) from Normal Human Bronchial Epithelial (NHBE) cell lines infected with SARS-CoV-2 (henceforth referred to as the CoV-2 dataset) and compared it with
lung epithelial cells infected with other respiratory infections,
namely, respiratory syncytial virus (RSV), influenza (H1N1),
and rhinovirus (RV16) using stringent study inclusion criterion (see Methods). Differentially expressed genes (DEGs)
were called for each infection (with respect to their respective
controls) using limma/voom, at an adjusted p-value < 0.05
(see Methods). We identified a total of 339, 27, 1781, and 208
DEGs in CoV-2, RSV, H1N1 and RV16 datasets, respectively,
with a more significant proportion of genes upregulated, in all
cases, in response to infection (Supplementary Table 1). Our
analysis indicated a significant over-representation of functional categories associated with immune response, across
all infections (among upregulated genes) (Fig. 1). The categories included, “response to virus”, “TNFα signaling via
NFκB”, “interferon response” (types I/α, II/γ ), and “apoptosis”. However, “coagulation” and “keratinocyte differentiation pathways” were among the top pathways to be uniquely
enriched within the CoV-2 dataset. Genes including ANXA1,
C1S, C3, CFB, F3, ITGB3, MAFF, MMP1, MMP9, PDGFB,
PLAT, PLAU, SERPINB2, TFPI2 associated with “coagulation” and S100A7, ANXA1, TGM1, IVL, and small prolinerich proteins SPRR2A, SPRR2E, SPRR2D, associated with the
“keratinocyte differentiation pathway” were among the 161
genes that were “uniquely” significantly upregulated within
the CoV-2 dataset (Fig. S1). Keratinocytes are known to be
associated with epithelial cell repair.
B. IDENTIFYING FUNCTIONAL MECHANISMS UNIQUE TO
SARS-COV-2 INFECTIONS

We posed the question if analyzing the molecular cascades associated uniquely with SARS-CoV-2, identified above, could
translate to findings that are relevant to thrombotic outcomes
seen in severe/acute COVID-19 patients [16]. To relate the
clinical and molecular phenotypes associated with SARSCoV-2 infection, we generated a protein interaction map
(strength > 0.85) from DEGs identified within the CoV-2
dataset (see Methods). We annotated this network with data
from the comparative analysis for the three other infections
(RSV, RV16, and H1N1). We subsequently clustered this
network, to identify “functional modules” relevant to the
pathology of SARS-CoV-2 infection. Our clustering identified
VOLUME 1, 2020

FIGURE 1. Functional enrichment of upregulated genes in upper
respiratory tract infections- Functional enrichment of upregulated genes in
upper respiratory tract infections- Functional enrichment of genes
upregulated upon infection with Rhinovirus (RV16), respiratory syncytial
virus (RSV), influenza (H1N1) and SARS-CoV-2 (CoV-2) were identified
using (a). mSigDB’s hallmark gene sets and (b). Gene ontology’s (GO)
biological process enrichment. No significant GO enrichment was
identified for RSV and hence not included in b. Enrichment illustrated the
biological functions common and unique to the different infections. Gene
ratios are indicated by the dots’ size and the adjusted p- value is by the
color scale indicated.

nine modules with five smaller functional modules containing genes associated uniquely with SARS-CoV-2, involving
angiogenesis, tubulins, keratinocytes, and small proline-rich
proteins (Fig. 2). Three of the four remaining modules were
mainly associated with immune response. These functional
modules included (i) genes associated with response to IFN
type I/III such as IFITM1, IFITM3, MX1, MX2, OAS1, OAS2,
IFIT1, IFIT3, and IRF9; (ii) Activation of the IL-17 proinflammatory cascades (IL6, IL1B, and CXCL1) via the TNFα
and NFκB signaling cascades (TNF, CSF2, CSF3, NFKB1,
NFKB2, RELB, and IRAK2) (iii) Signaling cascades downstream of interleukin response including JAK-STAT containing genes such as IL6R, STAT1, SOCS3, IFNGR1, and
PDGFB. Interestingly, though these modules were broadly
representative of vital immune mechanisms seen in all respiratory infections [17], [18], they also highlighted specific
mechanisms unique to SARS-CoV-2. For example, subversion
of innate immune response is inherent to cytopathic pathogens
like SARS-CoV (a related beta coronavirus), which causes
an increased release of pyroptosis products (e.g. IL-1B), inducing acute inflammatory responses. The antagonism of an
interferon response by SARS-CoV viral proteins has been
221
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FIGURE 2. Protein interaction network for SARS-CoV-2 infection- The protein-protein interaction network extracted for genes differentially regulated
(DEGs) in CoV-2 dataset (see Methods) is shown here. Clustering identified nine functional modules for further analysis. The modules functionally
corresponded with i. Response to interferon, ii. Cytokine-mediated & NFkB signaling iii. Complement & coagulation iv. JAK-STAT signaling v. Cell
proliferation vi. Gap junction pathway vii. Cytokeratins viii. Keratinocyte differentiation and ix. Angiogenesis. Red node labels indicate upregulated genes
and blue node labels indicates downregulated genes. Diamond node shapes indicate DEGs identified only within CoV-2 while circle indicate DEGs
identified in more than one upper respiratory tract infection.

suggested to occur at multiple stages of the interferon and
NFKB signaling cascades, through multiple mechanisms, including IKBKE and TRAF3 regulation, affecting downstream
STAT1 associated signaling [19]. It is possible that, in the
SARS-CoV-2 infection, the observed upregulation of IKBKE,
TRAF3, NFKB1, NFKB2, RELB, and IRAK2 at 24hpi could
be a consequence of similar mechanisms [2] The fourth large
module, contained genes specifically activated within the
CoV-2 dataset, involved in fibrinolysis and plasminogen activation cascades (PLAT, PLAU, PLAUR, and SERPINB2), the
complement activation cascade including C3, CSB, CXCL5,
and platelet aggregation (platelet activation factor receptorPTAFR (Fig. 2)). This module was particularly noteworthy
given the enrichment results (Fig. 1A) and clinical findings
of COVID-19 [16]. It is analyzed further in the following
sections.
C. TRANSLATING FUNCTIONAL MECHANISMS MEDIATED
BY SARS-COV-2 INFECTIONS TO COVID-19

Plasminogen is the precursor of the serine protease plasmin,
a vital component of the fibrinolytic system, essential for ensuring immune cell infiltration and cytokine production [20].
Plasminogen can be activated to plasmin by two serine peptidases, the tissue tissue-specific (T-PA) and urokinase (U-PA)
222

plasminogen activators encoded by PLAT and PLAU, respectively. It has been previously reported for SARS-CoV and influenza infections that dysregulation of the urokinase pathway
including U-PA(PLAU) and its inhibitor PAI-1(SERPINE1)
might contribute to the severity of lung disease by altering
the dynamics of fibrin breakdown and intra-alveolar fibrin
levels and subsequently inflammation [21], [22]. We observed
a similar dynamic with SARS-CoV-2 infection albeit through
activation of tissue plasminogen, PLAT, and the inhibitor SERPINB2. T-PA (which is triggered when bound to fibrin) and
F3 (tissue factor, activated in CoV-2) levels are known to
correlate with d-dimer levels [23]. D-dimer, a product of fibrin
degradation by plasmin, is elevated in patients with COVID19 and has been identified as a marker for disseminated intravascular coagulopathy and a worse patient prognosis [24].
These findings indicate increased fibrinolytic activity, specifically via T-PA (PLAT) activation, in SARS-CoV-2 infections.
The outcome of any viral infection is mediated through
a complex interplay between viral and host proteins, which
allow for a coordinated innate immune response. Plasminogen
inhibitor (PAI)-1 (SERPINE1) has been reported to function
as an anti-viral factor capable of inhibiting extracellular maturation of influenza particles, specifically through their action
on TMPRSS2 [25]. A similar mechanism involving PAI-2
VOLUME 1, 2020

(SERPINB2) likely exists in SARS-CoV-2 infections. Additionally, T-PA (PLAT) has been reported to interact with ORF8
protein of SARS-CoV-2 virus [2]; however, its consequence
has not yet been elucidated. We hypothesize that if this interaction titrates out T-PA, it is likely to result in reduced levels
of plasmin, which could contribute to downstream thrombosis
events, as observed in COVID-19 patients [16]. Increased expression of PLAT validated this. Additionally, increased concentration of SERPINB2 is also likely to reduce plasmin levels
leading to thrombosis. The unique regulation of SERPINB2
and PLAT in SARS-CoV-2 infections and their subsequent
effect on viral- host interaction dynamics is worthy of further
investigation.
Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that facilitate leukocyte infiltration by breaking down the extracellular matrix (ECM) and basement
membrane. The genes MMP1 and MMP9 (both upregulated
specifically within the CoV-2 dataset, see Fig. 2) can also be
activated by plasmin in vivo and in vitro [26]. Additionally,
the degranulation of neutrophils by T-PA has been indicated
as a source for the increase of matrix metalloproteinase 9
(MMP-9) [27]. Given the observed increase in MMPs, and
their role in facilitating lung inflammation in ARDS (by enabling neutrophil migration and ECM breakdown) [28], it
will be essential to evaluate the impact of T-PA treatments
[29] on pulmonary remodeling (via MMPs) in patients with
severe/acute COVID-19.
We identified significant upregulation of several genes encoding components of the complement system, including C3,
CFB, and C1S, uniquely within the CoV-2 dataset, in contrast
to other upper respiratory tract infections (at 24 hpi). The
complement pathway is an integral part of the innate immune
response and is involved in immunosurveillance for pathogen
clearance (bacterial and many viral) [30]. It traditionally
serves as a vital link between the innate and the adaptive
immunity, mainly driving pro-inflammatory cascades. Several
chemokines/chemoattractants (CXCL5, CXCL6, CXCL3, and
CCL20) identified within this cluster can also be activated
by signaling events precipitated by complement activation
[31], p. 5]. Overstimulation of these chemokines, particularly
CXCL5, is known to cause destructive inflammatory lung
conditions in specific pathogenic models of lung disease [32].
Plasmin is known to activate complement cascade independently of established pathways (alternate, lectin, and
classical pathways) by cleaving C3 and C5 to functional
anaphylatoxins C3a and C5a, in vitro and animal model
studies [33]. Furthermore, there is increasing evidence for
the role of complement in coagulation. C3 binds fibrinogen and fibrin with high affinity and prolonging fibrinolysis
in a concentration-dependent manner [34]. Studies in animal models of thrombosis have identified a plasmin-driven
C5a generation capable of driving procoagulant cascades
[35]. Moreover, the presence of terminal complement components including C5b-9 (membrane attack complex/MAC),
C4d, and mannose-binding lectin (MBL)-associated serine
protease (MASP2) within the pulmonary microvasculature and
VOLUME 1, 2020

purpuric skin lesions of deceased COVID-19 patients [36].
MAC has been additionally suggested to promote neutrophil
adhesion via platelet activating factor (PAF)-mediated mechanisms [37]. We observe a unique activation of the PAF
receptor (PAFR, encoded by the gene PTAFR) within the
complement and coagulation cluster (Fig. 2). PAF is a potent activator of platelet aggregation as well as immune cell
types including macrophages and neutrophils [38]. PAF binding to PAFR activates several intracellular signaling events
including complement activation [39], and plays pathophysiological roles in molecular mechanisms underlying anaphylaxis, bronchial asthma, cystic fibrosis [40], and endotoxin
shock/sepsis [41]. It is a crucial mediator of systemic and
pulmonary hemodynamic changes, additionally contributing
to pulmonary edema [42], [43] fitting the COVID-19 lung
injury model [44]. Immune infiltration primed by interaction between complement system and PAF has been reported
previously. Specifically, C5a and PAF together can induce
massive eosinophil transmigration [45]. Eosinophils release
leukotrienes and lipids, which can cause further epithelial
damage and airflow obstruction [46]. Leukotrienes, C5a, and
PAF are also potent chemo-attractants of polymorphonuclear
leukocytes (neutrophils or PMNs), which can further activate
neutrophil extracellular traps (NETs) leading to pulmonary
damage seen in COVID-19 patients [47]. Given the ubiquity
of SARS-CoV-2 receptors and its ability to infect a broad
range of cell types [13], analysis of PTAFR activation patterns
in infected tissues (including vascular endothelial cells) could
provide further insights into increased platelet aggregation
(via PAF signaling) and the risk for arterial thrombosis seen
in severe/acute COVID-19 patients [16]. Vitamin-D is known
to attenuate ICAM1 and PTAFR expression and subsequently
NFκB mediated inflammation, in rhinovirus infections [48].
ICAM1 is a crucial mediator of inflammation and is suggested
to mediate eosinophil adhesion to airway epithelium [49].
Similar mechanisms can underly the recent reports on reduced
risk for COVID-19 infections after Vitamin-D supplementation, and provide evidence for PAF/PAFR mediated signaling
in the progression of COVID-19 [50].
III. DISCUSSION

The significant enrichment of mechanisms identified above
were indicative of active epithelial remodeling and provided evidence for a plasmin-mediated complement activation
within SARS-CoV-2 in contrast to other respiratory infections. We also identified mechanisms that might contribute to
increased inflammation via immune infiltration and platelet
aggregation, primed by the interactions between the complement system, plasmin and the PAF/PAFR. Our findings further
the understanding of modulation of hemostatic factors, affecting the mechanics of circulating fibrin and fibrin breakdown
products [3] and complement activation, underlying acute
thrombotic events including arterial thrombosis in COVID-19
patients [16].
In addition, analysis of DEGs from transcriptomic measurements in postmortem lung tissue from COVID-19 patients
223
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FIGURE 3. A schematic representation of the crosstalk between plasmin, complement, and platelet-activating systems in SARS-CoV-2 infection.
Plasminogen conversion is mediated by either by tissue-specific plasminogen activator (T-PA) or urokinase plasminogen activator (U-PA), whose activities
can be inhibited by the inhibitors, PAI-1 (SERPINE1) or PAI-2 (SERPINE2B). The conversion of plasminogen to active plasmin is critical for blood clot
breakdown. Failure to breakdown the clots (fibrinolysis) leads to thrombosis. Fibrinolysis can be inhibited by complement component C3. The
complement components C3 and C5 can be activated by plasmin in addition the classical, lectin, and alternative pathways. The anaphylatoxins, C3a and
C5a, interact and stimulate mast cells to degranulate, releasing histamine, cytokines, granulocyte-macrophage colony-stimulating factor, leukotrienes,
heparin, and several proteases that damage the tissues. Overstimulation of complement cascade leads to inflammation, cytokine storm resulting in
epithelial damage, and airflow obstruction that manifests as the acute respiratory distress syndrome (ARDS). Also, C5a and Leukotriene-bound PAF are
potent attractants of polymorphonuclear leukocytes (PMNs) to the site of damage. The recruited PMNs can release microbiocidal molecules and form the
neutrophil extracellular traps (NETs). NETs are proinflammatory and promote tissue damage, thrombus formation, and activate platelets. PAF is also
suggested to trigger pulmonary edema in models of acute lung injury. Degradation of the basement membrane/ ECM promote by matrix
metalloproteinases further promote immune cell infiltration and tissue damage. NETs, tissue injury, platelets-activating factors (PAF), T-PA (if
overexpressed), C3a and C5a activate platelets to aggregate on a fibrin scaffold to form clot. Clots and tissue injury lead to airflow obstruction that
manifests as acute respiratory distress syndrome (ARDS). Double arrows indicate association.

provided a partial insight into the mechanisms associated
with virus-altered epithelial function. Functional analysis of
DEGs identified with COVID-19 exhibited an upregulation
of similar immune cascades as those identified within the
CoV-2 dataset (Figs. S2 and S3). Significant correlation was
also identified for foldchanges between DEGs commonly regulated between COVID-19 lung and CoV-2 dataset (rho =
0.34). We present our current view of the crosstalk between
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plasminogen, complement and platelet-activating systems in
SARS-CoV-2 infection in Fig. 3.
We are cognizant that we cannot wholly ascribe all mechanisms observed within a single time point (24 hpi) as contributing to observed clinical pathology of COVID-19, given
the limited availability of relevant publicly available human
in vitro data. However, our analysis highlighted SARS-CoV-2
driven response of healthy lung epithelial cells and its ability
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to incite a misdirected cascade of interactions between the coagulation, complement activation, and proteins involved in the
fibrinolytic system. Using current knowledge of these three
systems and the analysis of the data from in vitro model systems we infer the consequences of this misdirected network of
interactions, namely, coagulation, inflammation, and vascular
leakage/pulmonary edema in the COVID-19 lung. Detailed
in vivo and in vitro studies will be required to better understand the viral-host dynamics with respect to T-PA (PLAT)
and PAFR (PTAFR) activation and the subsequent systemic
inflammatory responses, in symptomatic and asymptomatic
COVID-19 populations.
IV. CONCLUSION

Our analysis hypothesizes that managing the equilibrium between the complement, coagulation and platelet-activating
components can determine the overall biological activity and
the outcome of a disease severity in COVID-19. An investigation into the efficacy of complement inhibitors (such
as Eculizumab [51] or Compstatin [52]), and plasminogen
activators specifically for T-PA, combined with Vitamin-D
supplementation to alleviate symptoms in patients with severe/acute COVID-19, warrant exploration.
V. MATERIALS AND METHODS
A. DATA ACQUISITION

We analyzed the data recently published by Blanco-Melo
et al. [5] to gain mechanistic insights into the pathogenicity
of SARS-CoV-2. The published dataset contained multiple
cell lines treated with SARS-CoV-2 including NHBE, Calu3, A529 (with and without exogenous expression of ACE2)
in addition to COVID-19 lung and normal tissue samples
(available via GSE147507). Histogram of counts within normal and diseased lung samples indicated that one COVID-19
lung sample (Covid Lung 2, Fig. S4) is a likely an outlier
and was ignored from further analysis. Based on the sample
clustering results of the raw counts (Fig. S2.B), we limited
our analysis to NHBE/ normal human bronchial epithelial
cell lines (hence forth referred to as the CoV-2 dataset).
All available series (GSE) in GEO were extracted from the
gene expression omnibus with key words- “SARS-CoV”,
“MERS-CoV”, “RSV” or “respiratory syncytial virus”, “Influenza” and “Rhinovirus” for respiratory cell lines (NHBE
or BEAS-2B). Since the CoV-2 transcriptional data was processed at 24 hpi (hours post infection), we chose to compare
only those infections which had cell-lines at 24 hpi yielding the following series GSE3397, GSE71766, GSE100504,
GSE81909, GSE27973, and GSE28904. To limit the impact
of sequencing technologies, we utilized only Affymetrix, the
technology with the most coverage among the series considered. Applying the above stringent inclusion criteria yielded
3 GEO series GSE3397 [53] (RSV), GSE71766 [54] (Influenza/H1N1 and Rhinovirus/RV16) and GSE27973 [55]
(Rhinovirus/RV16). We, however, did not find studies on
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related beta-coronaviruses in NHBE/BEAS-2B cell lines
which matched our inclusion criterion.

B. DIFFERENTIAL EXPRESSION ANALYSIS

For the sake of reproducibility, we called differentially expressed genes (DEGs) at adjusted p.value <0.05, using
GEO2R for GSE3397, GSE71766 and GSE27973 comparing
infected cells with their respective mocks at 24 hpi only. The
DEGs called for GSE27973 were a subset of GSE71766 RV16
comparisons and subsequently ignored. Since these were microarray studies, we aggregated probes which were significantly differentially expressed, to gene names and calculated
a mean fold change (Supplementary Table 1) and considered
these for all comparisons outlined in the manuscript. We
utilized the same pipeline implemented in GEO2R to call
DEGs from CoV-2 data (using the limma-voom pipeline in
R). Low counts were filtered using the “FilterByExpression”
feature available through the edgeR package. “topTable” was
used to extract all samples under our significance threshold
of p.adj <0.05. We would additionally like to point out that
we reanalyzed the CoV-2 data using the DESeq2 protocol as
described in the original publication consistently identified
similar number of DEGs as detected through limma-voom.
For the comparision of COVID-19 lung biopsy sample against
two healthy tissue biopsies, we utilized the exact T-test via
“edgeR” to establish significance and extracted the significant
genes via “topTags”.

C. PROTEIN NETWORK CONSTRUCTION

The human protein-protein interaction network (PPIN) was
downloaded from STRINGdb (v 11.0) [56] for a combined
edge strength of >0.85. We extracted a SARS-CoV-2 infection relevant subnetwork from this PPIN using DEGs identified in the CoV-2 dataset. The resulting CoV-2 network
contained 272 nodes and 608 edges (Fig. S3). We additionally annotated this CoV-2 network with differential gene expression information (foldchange) identified in all infections,
if present, to allow us to identify DEGs unique to CoV-2.
Functionally relevant modules within this network were extracted using GLay clustering [57]. GLay is an implementation of the Girvan-Newman fast greedy community clustering
algorithm. Girvan-Newman algorithm identifies communities
by progressively pruning of edges to identify most densely
connected clusters. Clusters with >3 nodes were retained for
further analysis, resulting in a network size of 186 nodes and
9 clusters (Fig. 2). The clusters were named based on the most
prominent terms associated with each cluster as identified
using Enrichr [58]. All network analysis and clustering (via
the clusterMaker plugin) was performed in Cytoscape [59].
Functional enrichment was performed using gene ontology
(biological process) and mSigDB’s Hallmark genesets (v7.1).
All visualizations were generated via the ClusterProfiler library [60] available through R/Bioconductor.
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SUPPLEMENTARY MATERIALS

Supplementary figures (S1–S4) and an Excel file containing
supplementary tables identified in the main manuscript are
included online.
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